Blood

Vol. 145, Issue 17 Issue 17 2025
19
Articles

Articles in this Issue

Recycling is “bad to the bone” in patients with myeloma

Kevin C. Miller, Alexander M. Lesokhin Apr 24, 2025 pp. 1832-1833 10.1182/blood.2024027940

Non-V600E <i>BRAF</i> mutations and treatment for hairy cell leukemia

Evgeny Arons, Chin-Hsien Tai, Joshi Suraj et al. Apr 24, 2025 pp. 1957-1961 10.1182/blood.2024026894

Abstract We found 20 patients with an immunophenotype consistent with classic hairy cell leukemia and BRAF mutations other than just V600E. Fourteen had 1 non-V600E BRAF mutation and...

17(<i>R</i>)-Resolvin D1 protects against sickle cell–related inflammatory cardiomyopathy in humanized mice

Enrica Federti, Domenico Mattoscio, Antonio Recchiuti et al. Apr 24, 2025 pp. 1915-1928 10.1182/blood.2024024768

Abstract Cardiovascular disease has been recognized as the main cause of death in adults with sickle cell disease (SCD). Although the exact mechanism linking SCD to cardiomyopathy re...

Seeing is believing: a histology textbook’s dream case of sarcoidosis

Pravin Patel, Olga Pozdnyakova Apr 24, 2025 pp. 1962-1962 10.1182/blood.2025028699

CAR T cells in autoimmunity: game changer or stepping stone?

Dimitrios Mougiakakos, Everett H. Meyer, Georg Schett Apr 24, 2025 pp. 1841-1849 10.1182/blood.2024025413

Abstract The advent of chimeric antigen receptor (CAR) T cells has revolutionized the treatment landscape for hematologic malignancies, and emerging evidence suggests their potential...

Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL

Weina Zhang, Jiaoyang Cai, Xiang Wang et al. Apr 24, 2025 pp. 1890-1902 10.1182/blood.2024026381

Abstract We evaluated the prognostic and therapeutic significance of measurable residual disease (MRD) during remission induction in pediatric patients with acute lymphoblastic leuke...

Emerging biomarkers for CD3×CD20 bispecific antibodies in lymphoma

Cameron S. Lewis, Allison Barraclough, Eliza A. Hawkes Apr 24, 2025 pp. 1850-1857 10.1182/blood.2024025772

Abstract Novel CD3×CD20 bispecific antibody (BsAb) immunotherapies have entered the armamentarium for follicular lymphoma and diffuse large B-cell lymphoma based on accelerated appro...

Targeting <i>Enterobacter cloacae</i> attenuates osteolysis by reducing ammonium in multiple myeloma

Qin Yang, Yinghong Zhu, Xingxing Jian et al. Apr 24, 2025 pp. 1876-1889 10.1182/blood.2024025694

Abstract Multiple myeloma (MM)-induced bone disease affects not only patients’ quality of life but also their overall survival. Our previous work demonstrated that the gut microbiome...

Methotrexate and glucarpidase: the emperor has new clothes

Stefan Schwartz, Jesper Heldrup Apr 24, 2025 pp. 1829-1830 10.1182/blood.2024027791

Common hereditary variants of the <i>APOE</i> gene and posttransplant outcome in acute myeloid leukemia

Julian Ronnacker, Michael Grau, Maximilian Klasmeier et al. Apr 24, 2025 pp. 1943-1956 10.1182/blood.2024026886

Abstract Apolipoprotein E (APOE) has multiple functions in metabolism and immunoregulation. Its common germ line variants APOE2, APOE3, and APOE4 give rise to 3 functionally distinct...

Functional assessment of genetic variants in thrombomodulin detected in patients with bleeding and thrombosis

Christine Van Laer, Renaud Lavend’homme, Sarissa Baert et al. Apr 24, 2025 pp. 1929-1942 10.1182/blood.2024026454

Abstract Thrombomodulin (TM) expressed on endothelial cells regulates coagulation. Specific nonsense variants in the TM gene, THBD, result in high soluble TM levels causing rare blee...

Glucarpidase for treatment of high-dose methotrexate toxicity

Shruti Gupta, Sarah A. Kaunfer, Kevin L. Chen et al. Apr 24, 2025 pp. 1858-1869 10.1182/blood.2024026211

Abstract High-dose methotrexate (MTX) results in high rates of acute kidney injury (AKI), neutropenia, and hepatotoxicity. Glucarpidase is a recombinant enzyme that cleaves MTX, but...

PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells

Lingli He, Ting Zhao, Wei Zhong Leong et al. Apr 24, 2025 pp. 1903-1914 10.1182/blood.2024026040

Abstract Differentiation arrest and dependence on oxidative metabolism are features shared among genetically diverse acute myeloid leukemias (AMLs). A phenotypic CRISPR-CRISPR–associ...

Thrombophilic thrombomodulin variants

Elisabetta Castoldi Apr 24, 2025 pp. 1837-1839 10.1182/blood.2024027934

STINGing leukemia stem cells through PSTK inhibition

Sylvain Garciaz Apr 24, 2025 pp. 1833-1835 10.1182/blood.2024028046

17(<i>R</i>)-Resolvin D1: a novel approach for SCD cardiomyopathy

Thilina U. Jayawardena, Gavin Y. Oudit Apr 24, 2025 pp. 1835-1837 10.1182/blood.2025028490

Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study

Ioannis Mantzaris, Mendel Goldfinger, Matan Uriel et al. Apr 24, 2025 pp. 1870-1875 10.1182/blood.2024026700

Abstract Venetoclax (Ven), when combined with intensive chemotherapy, shows promise for untreated acute myeloid leukemia (AML), but its integration with the 7+3 regimen remains under...

A new variable to study in transplant: <i>APOE</i> variant status

Satoshi Kaito, Susan DeWolf Apr 24, 2025 pp. 1839-1840 10.1182/blood.2025028406

Beyond conVENtional 7+3 in acute myeloid leukemia

Christine M. McMahon Apr 24, 2025 pp. 1831-1832 10.1182/blood.2025028442

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page